Tag - SPRO

Developments

Spero Therapeutics reports positive topline results from Phase 3 UTI and acute pyelonephritis trial

Spero Therapeutics (NASDAQ:SPRO) reported topline results from its Phase 3 ADAPT-PO trial evaluating tebipenem HBr for the treatment of complicated urinary tract infection (UTI) and acute pyelonephritis. Hospitalized...

September 8, 2020

Markets

Janney starts Spero Therapeutics at buy; fair value estimate $27

Janney Montgomery Scott initiated coverage of Spero Therapeutics (NASDAQ:SPRO) with a “buy” rating and fair value estimate of $27. The stock closed at $9.98 on Sept. 6. Analyst Esther Hong writes that her initiation is...

September 9, 2019

Tag - SPRO

Spero Therapeutics reports positive topline results from Phase 3 UTI and acute pyelonephritis trial

Janney starts Spero Therapeutics at buy; fair value estimate $27

General

More